High-Dose chemo combo shows promise for tough breast cancers

NCT ID NCT00066443

Completed Disease control Sponsor: NCIC Clinical Trials Group Source: ClinicalTrials.gov ↗

First seen Apr 03, 2026 · Last updated May 24, 2026 · Updated 5 times

Summary

This study tested a combination of two chemotherapy drugs (epirubicin and docetaxel) at increasing doses, along with a drug to help the immune system recover (pegfilgrastim), in 93 women with locally advanced or inflammatory breast cancer. The goal was to see how well the treatment shrank tumors and what side effects occurred. The study was completed, and results were shared in 2010.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Atlantic Health Sciences Corporation

Saint John, New Brunswick, E2L 4L2, Canada
CHA-Hopital Du St-Sacrement

Québec, Quebec, G1S 4L8, Canada
CancerCare Manitoba

Winnipeg, Manitoba, R3E 0V9, Canada
Odette Cancer Centre

Toronto, Ontario, M4N 3M5, Canada
Univ. Health Network-Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

Conditions

Explore the condition pages connected to this study.

BREAST CANCER